Low-margin distributors don't usually grow EPS 35% in a quarter. Cardinal Health just did — and then lifted its full-year adjusted EPS outlook above $10. When a defensive giant prints numbers like that, the market re-rates the multiple, not just the estimate, and that re-rating is where the money is.
Why it moved
The headline is the guidance raise. The story underneath is optionality. Cardinal is pushing cell-and-gene therapies into outpatient and community settings — exactly where volume scales — and expanding Actinium-225 radiopharmaceutical production in Indianapolis. That's a higher-return growth layer bolted onto a steady, cash-generative base.
| Metric | Reading |
|---|---|
| FY26 adj. EPS outlook | $10+ |
| Last quarter revenue | +11% YoY |
| Last quarter adj. EPS | +35% YoY |
| Analyst ratings | 14 buy / 3 hold / 0 sell |
| Avg. price target | ~$244 |
| Price (June 6, 2026) | $203.43-$208.00 |
What it means for you
Consensus is Moderate Buy with zero sells, and the ~$244 average target implies meaningful upside from the $203-$208 range — but that upside leans on the radiopharma ramp converting into reported margin, not press releases. If Actinium-225 volume shows up in the next print, the optionality stops being a story and becomes a number; if it doesn't, you're left paying up for a low-growth distributor.
Bottom line: I'd accumulate CAH on weakness for the defensive base and treat the radiopharma kicker as free optionality — but I'm waiting for the next print to confirm the ramp before sizing it up.